Healthcare has settled back into its normal late summer routine, with relatively little in the way of new product introductions or other market-moving data. That's not to say that the space is entirely quiet, though, as business continues to go on.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Novo Continues to Drive One of the Greatest Growth Stories in Healthcare
Very few healthcare stocks are as expensive as Novo Nordisk (NYSE:NVO), but few companies deserve that sort of premium either. There aren't too many companies with multiple billions of dollars in revenue that are growing more than 20%, but Novo is managing to do so largely on the strength of its diabetes franchise. Novo Nordisk stands tall alongside Lilly (NYSE:LLY) and Sanofi (NYSE:SNY) in the insulin space, while its Victoza remains a leading pharmaceutical option for Type 2 diabetes.

While the FDA approval timeline for a new insulin product has slipped a bit, and the company does face a potentially rejuvenated competitor now that Bristol-Myers (NYSE:BMY) and AstraZeneca (NYSE:AZN) have completed the deal for Amylin and its long-acting Bydureon (a direct competitor to Victoza).

Another Alzheimer's Drug Fails
Last week, Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) announced that they were more or less pulling the plug on their drug bapineuzumab for Alzheimer's. Not only did the companies announce a second Phase 3 trial failure, but also the companies are no longer intending to develop IV bapi any further. While an earlier stage Phase 2 subcutaneous trial continues, there is no particular reason to believe that this drug has any prospects in the treatment of mild-to-moderate Alzheimer's.

This news also increases the pressure on Lilly with its own Alzheimer's drug solanezumab. Prior to Phase 3 data from J&J and Pfizer, most analysts had assigned a higher probability of success to bapineuzumab than solanezumab, but the latter drug is a larger component of Lilly's potential pipeline revenue. In other words, Lilly's odds are worse but its needs are greater.

SEE: Investing In The Healthcare Sector

New Developments
Investors saw the week of August 13th start off with news that Sun Pharmaceutical and Taro Pharmaceutical (NYSE:TARO) managed to find common ground on a deal. Sun already owned two-thirds of Taro, but the company had rejected a prior offer of $24.50. With the offer hiked 60% to nearly $40 a share, though, Taro found a deal it could accept and will become wholly owned by Sun.

Pfizer is moving ahead with its asset monetization plans, announcing the filing of registration documents for the IPO of Zoetis - its animal health business. While the IPO is only scheduled to raise about $100 million, it should allow Pfizer to pursue a gradual divestment strategy for a business with more than $4 billion in revenue. It's also worth noting that while animal health is a sizable market, most animal health businesses are locked up inside larger companies and Zoetis will be a rare pure play for investors.

SEE: What Is a Pure Play?

The Bottom Line
The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit. The Health Care Select Sector SPDR (ARCA:XLV) is up 11.8% year-to-date, slipping below the the 12.2% return of the S&P 500. The iShares Dow Jones U.S. Pharmaceuticals ETF (ARCA:IHE) is up 14%, while the iShares Dow Jones U.S. Medical Devices ETF (ARCA:IHI) is up 10.7%. The SPDR Biotech ETF (ARCA:XBI) has risen almost 28% year-to-date.

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Personal Finance

    Protect Your Home From Medicaid Liens

    Plan ahead for long-term care needs to protect your home and your estate.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Nasdaq Biotech

    Obtain information about an ETF offerings that provides leveraged exposure to the biotechnology industry, the ProShares UltraPro Nasdaq Biotech Fund.
  4. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  5. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  8. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  9. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  10. Stock Analysis

    5 Reasons Thoratec Corp. Keeps Impressing Investors

    Learn about Thoratec Corporation and its position in its industry. Understand five key factors why the company has impressed investors.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Medical Identity Theft

    Stealing another person’s health insurance information so that ...
  3. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  4. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  5. Case Management

    Planning, processing and monitoring the healthcare services given ...
  6. Medical Patent

    A legal protection against market competition that a government ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. What role does the agency problem play in the modern Health Care industry?

    Agency problems vary from health care system to health care system, and not all economists agree on the degree and desirability ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!